Drug Profile


Alternative Names: 851A; 851B; epetirimod esylate; R851; S-30563; S-30563-35-65; TAK-851

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator 3M Pharmaceuticals
  • Developer Takeda
  • Class Antineoplastics; Antivirals
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cervical dysplasia; Human papillomavirus infections

Most Recent Events

  • 19 Nov 2013 Profile reviewed - prompted by Wendy's request (via Indu) re CTP18853. Matched R-851 with Epetirimod and requested changes in Thes; only two terminated trials on CT.gov, Takeda's pipeline of October 31, 2013 (TAK-851 no listed); added gel formulation
  • 01 Feb 2009 Discontinued - Phase-II for Cervical dysplasia in Canada (Topical)
  • 01 Feb 2009 Discontinued - Phase-II for Cervical dysplasia in European Union (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top